

educational objectives

At the conclusion of this activity, participants should be better able to:

- Discuss predictive factors for major bleeding and mortality risks in the treated ACS patient
- Evaluate the efficacy of peri-interventional administration of antithrombotic agents for the short- and long-term prevention of myocardial infarction and refractory ischemia
- Assess the short- and long-term effects of targeted anticoagulants and heparins on major bleeding events in ACS

intended audience

This program has been designed for interventional cardiologists.

faculty

Jeffrey J. Popma, MD—Program Moderator

Director, Interventional Cardiology
Associate Professor of Medicine
Brigham and Women's Hospital
Harvard Medical School
Boston, Massachusetts

James J. Ferguson III, MD

Associate Director, Clinical Cardiology Research
Texas Heart Institute
Houston, Texas

William H. Matthai, Jr, MD

Clinical Associate Professor of Medicine
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania

It is the policy of Educational Review Systems to ensure balance, independence, objectivity and scientific rigor in all presentations. Speakers are required to disclose any discussion of unlabeled or investigative use of any commercial product.

Relationships between commercial supporters and faculty, either perceived or real, will be openly disclosed and disseminated at the TCT meeting.

This program is supported by an unrestricted educational grant from GlaxoSmithKline.



Produced by Continuing Edge,
a division of Global Edge, Inc.
© 2006 Global Edge, Inc., New York, NY
All rights reserved; printed in USA, Sept 2006; 6-158

New Anticoagulant Strategies to Reduce Bleeding and Mortality in Acute Coronary Syndromes

Thursday, October 26, 2006

8:00-10:00 PM

**Grand Ballroom
Renaissance Washington, DC Hotel
999 Ninth Street NW
Washington, DC**

**7:30-8:00 PM Dinner and
Registration**

8:00-10:00 PM Program

A Continuing Education Dinner Symposium taking place at



TRANSCATHETER CARDIOVASCULAR THERAPEUTICS


program overview

Advances in treating acute coronary syndromes (ACS) have greatly reduced the risk of cardiac death following the first episode (ie, unstable chest pain, acute myocardial infarction). However, with the improvements in control of ischemia now possible, bleeding has emerged as a potentially more serious threat, resulting in a significant shift in the major mortality risk for ACS patients.

Predictors such as advanced age, female sex, history of bleeding, and renal insufficiency have been identified as being independently associated with a higher risk of bleeding. Furthermore, emerging evidence indicates the administration of antithrombotic agents within 24 hours of the ACS episode can have important effects on both short- and long-term mortality risk associated with both cardiac events and major bleeding events. In this context, the selection of the antithrombotic agent has particular importance, and recent data from large clinical trials with selective factor Xa inhibitors and low-molecular-weight heparins support the notion that different agents are associated with varying mortality and major bleeding risks.

This symposium will present to the interventional cardiologist current clinical thought regarding the transitional use of anticoagulants in ACS, especially newer agents. Recent clinical trial data will be reviewed; clinical implications for the use of these agents in ACS patients will be a highlight of this program.

accreditation



This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education. Educational Review Systems (ERS) is accredited by the

ACCME to provide continuing medical education.

Educational Review Systems designates this educational activity for a maximum of 2.0 *AMA PRA Category 1 Credits*[™]. Each physician should claim only those hours of credit actually spent in the educational activity.

New Anticoagulant Strategies to Reduce Bleeding and Mortality in Acute Coronary Syndromes

8:00-10:00 PM
Grand Ballroom
Renaissance Washington, DC Hotel
999 Ninth Street NW
Washington, DC

Thursday, October 26, 2006

agenda

- 7:30-8:00 PM Registration and Dinner
- 8:00-8:10 PM Welcome and Introduction
Jeffrey J. Popma, MD
Program Moderator
Brigham and Women's Hospital
- 8:10-8:35 PM Changing Patterns of Risk and Outcomes in ACS: Now It's the Bleeding
James J. Ferguson III, MD
Texas Heart Institute
- 8:35-9:00 PM Other Risks: Percutaneous Coronary Interventions and Heparin-Induced Thrombocytopenia
William H. Matthai, Jr, MD
University of Pennsylvania School of Medicine
- 9:00-9:30 PM Assessing the Transitional Use of Anticoagulants in ACS: Practical Considerations from Recent Clinical Trial Data
Jeffrey J. Popma, MD
- 9:30-10:00 PM Questions and Answers
Faculty

To pre-register, please complete the enclosed fax form and return on or before Friday, October 20, 2006 to (212) 792-6659.

Should you have any additional questions or special needs, please contact Alexis Gabor at (212) 792-6631 or agabor@globaledge-us.com.

fax response

New Anticoagulant Strategies to Reduce Bleeding and Mortality in Acute Coronary Syndromes

Thursday, October 26, 2006
8:00-10:00 PM
Grand Ballroom
Renaissance Washington, DC Hotel
Washington, DC

PLEASE PROVIDE COMPLETE INFORMATION AND FAX TO:

212-792-6659

PLEASE RETURN THIS FORM BY FRIDAY, OCTOBER 20, 2006

IF A FAX MACHINE IS NOT AVAILABLE,
YOU MAY MAIL THIS FORM TO:

Alexis Gabor—Continuing Edge,
Continuing Edge, a division of Global Edge, Inc.
45 West 45th Street, New York, NY, 10036

Name

Affiliation

Telephone

Fax

E-Mail

Business Address:

City/State/Zip

Home Address:

City/State/Zip

